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Moderate aortic stenosis (AS) and reduced left ventricular ejection fraction (LVEF)
constitute a clinical entity that has been proposed as a therapeutic target for transcatheter
aortic valve replacement (TAVR). It is defined by a mean trans-aortic gradient between
20 and 40 mmHg and an aortic valve area between 1.0 and 1.5 cm2 in patients with
LVEF< 50%. Retrospective data suggests a prevalence of 0.8% among patients referred
for echocardiographic assessment. These patients are younger and show a higher
frequency of previous myocardial infarction than those with severe AS randomized to
TAVR in recent trials. In two retrospective studies including patients with moderate AS
and reduced LVEF, a one-year mortality rate of 9 and 32% was reported, the latter in
patients treated with medical therapy only during follow-up. Echocardiographic diagnosis
of moderate AS poses challenges as current guidelines are directed to determine
severe AS, and different presentations of moderate and mild AS have been generally
neglected. Thus, the nomenclature would need to be revised and a description of
possible scenarios is provided in this review. Dobutamine stress echocardiography and
computed tomography are promising complementary tools. Likewise, a standardized
clinical pathway is needed, in which a high level of suspicion and a low threshold for
referral to a heart valve center is warranted. The Transcatheter Aortic Valve Replacement
to UNload the Left ventricle in patients with Advanced heart failure (TAVR UNLOAD) trial
(NCT02661451) is exploring whether TAVRwould improve outcomes in patients receiving
optimal heart failure therapy.
Keywords: moderate aortic stenosis, left ventricular ejection fraction, transcatheter aortic valve replacement,
surgical aortic valve replacement, structural heart disease, TAVR UNLOAD trial
INTRODUCTION
Severe aortic stenosis (AS) is the most common indication for valvular interventions in adults.
It affects 3% of patients after 75 years of age (1). Earlier stages of the disease have been typically
disregarded as targets for aortic valve replacement (AVR) given an unfavorable risk-benefit balance.
Specifically, due to the relatively high rates of peri-procedural death or stroke with AVR, and
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the lack of evidence of a significant increased risk of events in
patients with mild to moderate AS treated medically (2). Better
characterization of high risk populations among patients with
moderate AS together with advancements of transcatheter aortic
valve replacement would identify a niche population potentially
benefiting from an earlier intervention (3–5).
In patients with moderate AS and concomitant reduced left
ventricular ejection fraction (LVEF< 50%), death or heart failure
hospitalization was observed in half of them at 4 years of follow-
up (5). It is noteworthy that pathophysiologically LVEF reduction
in this population is generally not attributed to AS, but rather to
myocardial damage due to ischemic conditions or non-ischemic
non-valvular cardiomyopathies. In this setting moderate AS may
contribute significantly to the overall ventricular afterload, and
contribute to systolic and diastolic dysfunctions and ultimately to
a progressive symptomatic status (6, 7). In patients with severe AS
and conservative treatment, reduced LVEF has been associated
with increased rates of death and heart failure hospitalizations
[hazard ratio (HR), 95% confidence interval (CI): 1.82 [1.44–
2.28], p < 0.001, when compared with LVEF > 70% by the
Teichholz or Simpson method] (8). In patients undergoing
AVR, reduced EF has also emerged as an independent predictor
of mortality at 5 years of follow-up, with an increase of
12% mortality [HR (95% CI) = 0.88 (0.83–0.94), p < 0.001]
for every 10% decrease in LVEF (9). Among patients with
moderate AS and reduced LVEF, male sex, New York Heart
Association (NYHA) functional class III and IV, and the peak
aortic jet velocity obtained with Doppler ultrasound emerged as
independent predictors of worse outcome (5). Advanced heart
failure symptoms (NYHA III or IV= 58%, NYHA II= 31%, and
NYHA I = 23%, at 2 years) as well as being admitted at the time
of diagnosis (60 vs. 34% at 2 years, p< 0.001), are associated with
increased rate of death, AVR or heart failure hospitalizations (5).
This review summarizes the frequency of concomitant
reduced LVEF and moderate AS, its natural history, differential
patient characteristics when compared with patients with severe
AS, diagnostic challenges, and further discusses the rationale of
the ongoing Transcatheter Aortic Valve Replacement to UNload
the Left ventricle in patients with ADvanced heart failure (TAVR
UNLOAD) trial (NCT02661451) (10).
Epidemiology and Natural History
Reduced LVEF is an established predictor of adverse events
including heart failure hospitalizations and death, and its severity
determines the treatment alternatives for a patient (11). One
to Two Percent of adults live with the diagnosis of heart
failure, with a lifetime probability of 1:3 to receive this diagnosis
after the age of 55 years (11) Reduced LVEF accompanies this
clinical syndrome in approximately 50% of cases. Ambulatory
patients with symptomatic reduced LVEF have a one year
risk of death of 7% and hospitalizations of 32%; whereas the
rates increase to 17 and 44% after one hospitalization (11).
Less is known for moderate aortic stenosis, since it is not a
target of medical therapy, as several attempts to decelerate the
progression of disease have failed (12–14). Moreover, surgical
aortic valve replacement (SAVR) is considered only when
moderate AS is diagnosed as a bystander in a patient undergoing
an open heart surgery for other conditions (15). Consequently,
in routine clinical practice, this condition is not prospectively
ascertained and streamlined for treatment, leading to difficulties
in determining its frequency.
An analysis of the Duke echocardiographic database
(N = 132,804) showed that 1.2% of patients would qualify for
the diagnosis of moderate or severe AS and reduced LVEF,
from which 0.8% had moderate and 0.4% had severe AS (16).
In an effort of extrapolation, for a center performing 5,000
echocardiograms per year, this would represent the diagnosis of
moderate AS and reduced LVEF in 40 patients per year. More
importantly, one third of patients with moderate AS included in
the aforementioned analysis did not survive more than one year
on medical treatment only (16). More optimistic results were
observed in a multi-center retrospective analysis, which showed
a one-year mortality rate of 9% in patients with moderate AS and
reduced LVEF, partially explained by a 13% rate of AVR at one-
year (5). Both studies ought to be contrasted with the 1.4% rate
of one-year mortality observed in the Simvastatin and Ezetimibe
in Aortic Stenosis (SEAS) trial, which randomized 1,873
patients with mild-to-moderate AS to an intensive cholesterol
lowering strategy (13). Contrary to the previous higher risk
cohorts, the SEAS trial included asymptomatic patients with no
atherosclerotic conditions, diabetes mellitus, or indication of
lipid-lowering therapy. Virtually all patients had LVEF above 50
and 30% had an aortic valve area (AVA) above 1.5 cm2, consistent
with mild AS. This comparison highlights the impact of LVEF
and AS severity on clinical outcomes.
The rate of progression of AS has been systemically assessed in
the SEAS and other randomized trials investigating the impact of
lipid-lowering therapies on the natural history of the disease (12–
14). Despite a significant reduction of low-density lipoprotein
cholesterol, the disease progression remained comparable among
study groups. A meta-analysis of statin trials reported an annual
increase in mean trans-aortic gradient of 2.8± 3.0 mmHg, and a
decrease in aortic valve area of 0.04± 0.27 cm2 (17). Uncertainty
remains on individual factors that may accelerate the progression
of the disease (e.g., smoking, serum creatinine), and individual
variation has been described with mean rates of progression as
high as an annual increase of 7 mmHg in mean gradient and
decrease of 0.1 cm2 in AVA (18).
Supportive evidence of the detrimental role of increased
trans-aortic gradients stems from research on prosthesis-patient
mismatch (PPM) after SAVR. PPM is present when the AVA of
the inserted valve is too small in relation to the body size of
the patient, which generates higher than expected trans-aortic
gradients (6). In a cohort of 2,576 patients who underwent SAVR,
severe PPM defined as an indexed AVA (AVAi) ≤ 0.65 cm2/m2,
was associated with increased late overall and cardiovascular
mortality, after adjustment for other known risk factors (6).
Importantly, moderate PPM (AVAi > 0.65 but ≤ 0.85 cm2/m2)
was also associated with increasedmortality {HR [95%CI]= 1.21
[1.03–1.41], p = 0.01} in patients with reduced LVEF (<50%)
only (6). Pathophysiologically, this suggests that patients with
impaired systolic function suffer from persistent higher-than-
normal afterload. Furthermore, recent evidence suggests that in
patients with AS, the decline in LVEF starts before AS is severe
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and accelerates after AVA reaches 1.2 cm2 (19). LVEF < 60% in
the presence of moderate AS has been suggested as a predictor of
further LVEF deterioration (19).
Hypertension is highly prevalent in patients with moderate
AS and reduced LVEF (5). Although not a direct component of
the disease, it determines the arterial component of the afterload.
The sum of the valvular and arterial components of the afterload
represents the valvulo-arterial impedance, (20) which is a strong
predictor of mortality in patients in different stages of AS,
ranging from moderate to severe asymptomatic patients up to
post-TAVR patients (21–23). In elderly patients who typically
have a reduced arterial compliance, means to reduce the arterial
component of the overall LV afterload with medical therapy
i.e., anti-hypertensive drugs, are limited. In this clinical setting
AVR for even moderate AS may eventually be the only option
to further reduce the valvulo-arterial impedance and improve
outcome (10).
Aortic Valve Replacement
Current clinical practice guidelines recommend SAVR in patients
with moderate AS undergoing CABG or surgery of the ascending
aorta or of another valve (class of recommendation IIa and a level
of evidence C) (15, 24) Moreover, Patients undergoing CABG
before 70 years of age with a peak gradient above 30 mmHg and
a documented yearly progression of 5 mmHg, may benefit from
SAVR (2). These represent the only two mentions of moderate
aortic stenosis in the ESC/EACTS guidelines for management of
valvular heart disease, and are largely supported by retrospective
data (15). Such interventions are referred to as “prophylactic
SAVR,” aiming to avoid a second open-heart procedure. A post-
CABG SAVR procedure is exposed to the risk of damaging patent
grafts including the internal mammary arteries; is technically
challenging due to calcified aortic arches and scarring of the
mediastinum; and procedural mortality has been reported in up
to 16% of patients (25, 26) In patients with prior CABG that
require AVR, TAVR is progressively replacing SAVR (26). In
a propensity-matched analysis including 3,880 record in each
group, TAVR and SAVR showed similar in-hospital mortality (2.3
vs. 2.4%, p= 0.71) but TAVRwas associated with lower incidence
of procedural complications including myocardial infarction
(1.5% vs. 3.4%, p < 0.001), stroke (1.4 vs. 2.7%, p < 0.001),
bleeding (10.6 vs. 24.6%, p< 0.001), and acute kidney injury (16.2
vs. 19.3%, p < 0.001). Consequently, the rationale of exposing
the patient to a prophylactic SAVR in order to avoid a second
open-heart surgery is currently challenged (26).
The concept of “therapeutic” TAVR in patients with moderate
AS is evolving (10). In a retrospective analysis of 1,090 patients
with moderate AS and reduced LVEF, SAVR within 90 days vs.
no intervention, was associated with a 41% reduction of all-
cause mortality after a median follow-up time of 1.2 years (16).
Moreover, this benefit remained in a sub-group of patients with
reduced LVEF without coronary artery disease (16).
Patient Characteristics
Patients with moderate AS and reduced LVEF are younger and
show a higher frequency of prior acute myocardial infarction
than patients with severe AS typically included in randomized
trials (see Table 1) (3, 5, 16, 29, 32). Importantly, prospective
randomized trials comparing TAVR vs. SAVR in bicuspid aortic
valve disease may provide guidance on the preferred approach
for such sub-group, which has been largely excluded from TAVR
studies. Post-TAVR incidence of moderate to severe paravalvular
leak and new pacemaker implantation has been more frequently
observed in patients with bicuspid anatomy (33). Furthermore,
it remains unclear whether there is a preferred device, being a
balloon-expandable, self-expandable, or mechanically-expanded
transcatheter heart valve, when treating patients in potential need
for a re-do procedure due to an expected longer life expectancy
(34, 35).
Challenges
Three main challenges exist for promoting “therapeutic” TAVR
in patients with moderate AS and reduced LVEF: (1) better
understanding of the echocardiographic diagnosis of moderate
AS, (2) defining a clinical pathway to identify patients, and
(3) evidence from randomized trials supporting TAVR in this
population.
Echocardiographic Diagnosis of Moderate
Aortic Stenosis
Moderate AS is characterized by a mean trans-aortic gradient
between 20 and 40 mmHg and an AVA between 1.0 and 1.5 cm2.
Other findings include a peak velocity of the trans-aortic flow
between 3.0 and 4.0 m/s, a velocity ratio between 0.25 and 0.50,
and an indexed AVA by body surface area between 0.60 and
0.85 cm2/m2 (36). When findings are concordant (e.g., mean
gradient between 20 and 40 mmHg and AVA between 1.0 and
1.5 cm2), the diagnosis is clear-cut. However, discordant findings
are frequently observed (e.g., AVA < 1.0 cm2 and mean gradient
between 20 and 40 mmHg; or, AVA between 1.0 and 1.5 cm2 and
mean gradient < 20 mmHg), especially in the context of reduced
LVEF.
In Figure 1we summarize the different scenarios that could be
observed when evaluating a patient with AS. Our understanding
of severe AS has increased significantly in the last two decades,
and the most recent classification of patients includes sub-groups
based on gradient (low-gradient: mean gradient < 40), ejection
fraction (abnormal<50%) and flow status (low flow< 35ml/m2)
(36). All flow-gradient patterns, stratified by LVEF, have been
reported in patients with severe AS (36–38). When findings
for severe AS are discordant in patients with reduced LVEF
(AVA < 1 cm2 and mean gradient < 40 mmHg) patients are
assessed with a low-dose dobutamine stress echocardiogram
(DSE) to differentiate among “true severe” AS vs. “pseudo-severe”
AS (e.g., moderate AS) (36). Likewise, the difference between
mild AS and moderate AS would need to be established through
a DSE if therapeutically relevant. For descriptive purposes,
Figure 1 creates AS groups based on the following parameters:
(1) AS severity is concordant if the AVA and the mean gradient
match the same category (i.e., mild, moderate or severe), and if
not, AS severity is defined as discordant; (2) In this description,
the gradient is not defined as “high” or “low” gradient, but
rather in relationship with the category it applies (i.e., mild,
moderate, or severe); (3) sub-groups can be further classed
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FIGURE 1 | Possible scenarios observed in patients with aortic stenosis including sub-groups according to ejection fraction and flow patterns. Concordant findings
between aortic valve area and transvalvular gradient do not pose diagnostic challenges. However, discordant findings require additional tests to define the appropriate
category (e.g., dobutamine stress echo, CT-derived aortic valve calcium score, 3D-echo or CT-derived left ventricular outflow tract area). Interpretation of findings are
better stablished for categories 2 and 3 (true severe vs. pseudosevere aortic stenosis); however, knowledge is evolving for categories 6 and 7. Patient with high
transvalvular flow should be classified after determining if the mechanism of high flow is reversible (e.g., fever, anemia) or irreversible (e.g., concomitant aortic
regurgitation). Categories 8 and 11 correspond to reversible causes, and 5 and 10 to irreversible causes. Patients with aortic stenosis can be further categorized
based on ejection fraction and flow status. AVA = aortic valve area; MG = mean gradient.
based on LVEF (above or below 50%) and flow status (above
or below 35 ml/m2). With this description, “pseudo-severe AS”
would be referred to as “discordant moderate-gradient moderate
AS.” It is “discordant” because initially the AVA would be
compatible with severe AS (<1 cm2) but the gradient with
moderate AS (<40 mmHg). All initially discordant cases need
further evaluation in order to be properly classified, especially
with concomitant reduced LVEF: (1) make sure that there are
no technical pitfalls in the measurement of the mean gradient
(e.g., misalignment of the Doppler signal with the direction
of the flow, inadvertent recording of mitral regurgitation) or
the AVA (e.g., underestimation of the left ventricular outflow
tract diameter); (2) if LVEF is the factor that could potentially
influence the gradient and aortic valve opening, a low-dose DSE
is indicated, starting at 2.5 or 5 µg/kg/min with a progressive
increase in the infusion every 3–5min to a maximum dose of
10–20 µg/kg/min; (36) (3) in the absence of contractile or flow-
reserve, the computed tomography aortic valve calcium score
helps to determine the likelihood of having severe AS (e.g., likely
if ≥ 2000 in men, and if ≥ 1200 in women) (36). Currently,
there is insufficient data to differentiate mild from moderate
AS based on calcium score; (4) increased gradient due to high
trans-valvular flow should be considered as an option in patients
with discordant findings. When causes are reversible (e.g., fever
or anemia), patients should be reassessed after correcting the
causes. When causes are irreversible (e.g., significant aortic
regurgitation), patients should be categorized according to the
gradient severity and treatment should be offered accordingly.
These concepts open a new era in the diagnosis of aortic
stenosis, and registry data as well as retrospective analysis may
help us clarify the need for an updated nomenclature, which
would require a joint effort of cardiology societies.
Clinical Pathway for Moderate Aortic
Stenosis and Reduced LVEF
Offering TAVR to patients with moderate AS and reduced LVEF
would be a change of a clinical paradigm. Due to the currently
non-existing treatment alternatives apart from established heart
failure therapies, these patients do not fall into any specific
clinical pathway. If these patients were to be offered TAVR,
imaging will play a pivotal role. Patients with moderate AS and
reduced LVEF may be referred within the same institution or
through other referral institutions due to symptoms, physical
exam (e.g., systolic murmur), or screening echocardiogram.
Severity of AS in the context of reduced LVEF may need to
be confirmed with a DSE (if initial findings are discordant).
Moreover, once the diagnosis is confirmed technical plausibility
of TAVR needs to be assessed by means of a pre-TAVR multi-
slice computed tomography. Current evidence supports the use
of transfemoral over non-transfemoral access for TAVR, given a
lower rate of procedural complications (e.g., acute kidney injury,
need for renal replacement therapy) and lower 1 year mortality
(39, 40). Thus, a transfemoral approach should be considered as
first option for this high risk population, commonly avoiding the
need of general anesthesia. Most patients would have coronary
artery disease, and a coronary angiogram would need to be
included in the clinical work-up.
It is essential to refer potential candidates to experienced
heart valve centers (15). A high grade of suspicion and low
threshold for referral would be required from non-interventional
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cardiologists and other specialties. Moreover, a systematic
echocardiographic assessment of the AVA in all patients with at
least mild AS gradient, would potentially help to identify patients
with “discordant mild-gradient moderate AS,” which would
otherwise have been missed. Nevertheless, current evidence
recommends watchful waiting and periodic echocardiographic
follow-up in patients with moderate AS and reduced LVEF. This
approach may significantly change if results of ongoing trials
prove to be clinically meaningful.
TAVR UNLOAD Trial
The single most important requirement to promote TAVR as a
therapeutic option in patients with moderate AS and reduced
LVEF is to create confirmatory prospective evidence that this
intervention is clinically meaningful (5, 6, 16). The Transcatheter
Aortic Valve Replacement to UNload the Left ventricle in
patients with Advanced heart failure (TAVR UNLOAD) trial
(NCT02661451) is an international, multicenter, randomized,
open-label, clinical trial comparing TAVR with the Edwards
SAPIEN 3 Transcatheter Heart Valve in addition to optimal
heart failure therapy (OHFT) vs. OHFT alone in patients
with moderate AS and reduced LVEF (10). This trial is
currently enrolling patients in The Netherlands, Canada, and
the United States of America. Screening of patients includes
echocardiographic eligibility assessment by an independent
Core Laboratory, which centrally confirms the presence of
moderate AS and reduced LVEF. Assessment may include a DSE.
Importantly, written confirmation of OHFT is provided by a
local heart failure specialist. Clinical, imaging, and procedural
eligibility are confirmed by a Central Screening Committee
before randomization. The primary endpoint, defined as the
hierarchical occurrence of all-cause death, disabling stroke,
hospitalizations related to HF, symptomatic aortic valve disease
or non-disabling stroke, and the change in the Kansas City
Cardiomyopathy Questionnaire, will be analyzed at 1 year.
Changes in heart failure pharmacologic and device therapies will
be monitored. Moreover, echocardiographic endpoints will be
assessed up to 2 years. Findings may have a significant impact
on the way we diagnose, refer and manage patients with AS.
CONCLUSION
Patients with moderate AS and reduced LVEF are exposed to
a significant risk of clinical events including death. Indirect
evidence suggests that aortic valve replacement may offer a
clinically meaningful benefit. Incorporating this entity as a
therapeutic target requires re-assessment of how we diagnose AS
and improved strategies of referral. The TAVR UNLOAD trial
is investigating whether TAVR could improve clinical outcomes
including quality of life in this high risk population.
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